Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns
- Aarhus University Hospital, Denmark
- University of Copenhagen, Denmark
Abstract
DNA repair deficiencies in cancers may result in characteristic mutational patterns, as exemplified by deficiency of BRCA1/2 and efficacy prediction for PARP-inhibitors. We trained and evaluated predictive models for loss-of-function (LOF) of 145 individual DDR genes based on genome-wide mutational patterns, including structural variants, indels, and base-substitution signatures. We identified 24 genes whose deficiency could be predicted with good accuracy, including expected mutational patterns for BRCA1/2, MSH3/6, TP53, and CDK12 LOF variants. CDK12 is associated with tandem-duplications, and we here demonstrate that this association can accurately predict gene deficiency in prostate cancers (area under the ROC curve=0.97). Our novel associations include mono- or biallelic LOF variants of ATRX, IDH1, HERC2, CDKN2A, PTEN, and SMARCA4, and our systematic approach yielded a catalogue of predictive models, which may provide targets for further research and development of treatment, and potentially help guide therapy.
Data availability
This study is based on analyses of human germline and cancer somatic variant data. The data sets were generated and made available by the Pan-Cancer Analysis of Whole Genomes (PCAWG) consortium and from the Hartwig Medical Foundation (HMF). The majority of the data cannot be publicly accessed as it includes protected personal data, including germline variants, which cannot be made publicly available. However, accession to the underlying data sets can be achieved through applications to ICGC/TCGA and HMF as described below.The public parts of the PCAWG data set are available at https://dcc.icgc.org/releases/PCAWG, whereas controlled files may be accessed through applications to gbGaP and DACO, which should include a project proposal, as instructed on this site https://docs.icgc.org/pcawg/data/. The ICGC study ID of the project is EGAS00001001692.The HMF data used in this project may be found by accession code DR-044 and can be obtained by submitting an application with a project proposal to the Hartwig Medical Foundation (https://www.hartwigmedicalfoundation.nl/en).Non-personal summary data have been supplied in supplementary tables S1 to S9:Supplementary Table 1: All included tumours and their primary tumour locationsSupplementary Table 2: 736 DDR genes, hg19 coordinates and the number ofpathogenic events across 6,065 cancer genomesSupplementary Table 3: All SBS signature contributions, indels counts, and1104 SV counts, per sample; zip-compressed; tab-separated values (.tsv), may be opened in Microsoft ExcelSupplementary Table 4: All SBS signature contributions, indels counts, andSV counts, per sample, log-transformed and scaled to z-scores; zip-compressed; tab-separated values (.tsv), may be opened in Microsoft ExcelSupplementary Table 5: Proposed Etiologies of base substitution signaturesSupplementary Table 6: All models (n=535)Supplementary Table 7: Pathogenic events in each of the 535 LOF-setsSupplementary Table 8: Shortlisted models (n=48)Supplementary Table 9: Correlation between features in shortlisted modelsSupplementary Table 10: Survival analysis for the shortlisted modelsThe third-party software used for data analysis includes:Pathogenicity annotation using CADD annotation software, which may be accessed at https://cadd.gs.washington.eduSignature analysis using Signature Tools Lib, which has been installed from the GitHub: https://github.com/Nik-Zainal-Group/signature.tools.libCode that we developed locally for the analysis can be accessed at:https://github.com/SimonGrund/DDR_Predict
Article and author information
Author details
Jakob Skou Pedersen
Funding
Novo Nordisk Fonden (NNF15OC0016662)
- Eva R Hoffmann
Cancer Research UK (C23210/A7574)
- Eva R Hoffmann
Danmarks Frie Forskningsfond (8021-00419B)
- Jakob Skou Pedersen
Kræftens Bekæmpelse (R307-A17932)
- Jakob Skou Pedersen
Aarhus Universitets Forskningsfond (AUFF-E-2020-6-14)
- Jakob Skou Pedersen
Sundhedsvidenskabelige Fakultet, Aarhus Universitet (PhD stipend)
- Simon Grund Sørensen
Sundhed, Region Midtjylland (A2972)
- Gustav Alexander Poulsgaard
Danmarks Grundforskningsfond (DNRF115)
- Eva R Hoffmann
The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.
Reviewing Editor
- W Kimryn Rathmell, Vanderbilt University Medical Center, United States
Ethics
Human subjects: We analysed data generated and made available by the Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium of the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) as well as the Hartwig Medical Foundation (HMF). The research conforms to the principles of the Helsinki Declaration.
Version history
- Preprint posted: February 3, 2022 (view preprint)
- Received: June 20, 2022
- Accepted: February 26, 2023
- Accepted Manuscript published: March 8, 2023 (version 1)
- Version of Record published: April 19, 2023 (version 2)
Copyright
© 2023, Sørensen et al.
This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.
Metrics
-
- 1,519
- views
-
- 303
- downloads
-
- 1
- citations
Views, downloads and citations are aggregated across all versions of this paper published by eLife.
Download links
A two-part list of links to download the article, or parts of the article, in various formats.
Downloads (link to download the article as PDF)
Open citations (links to open the citations from this article in various online reference manager services)
Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)
Pan-cancer association of DNA repair deficiencies with whole-genome mutational patterns
eLife 12:e81224.
https://doi.org/10.7554/eLife.81224
Further reading
-
- Cancer Biology
Dormancy in cancer is a clinical state in which residual disease remains undetectable for a prolonged duration. At a cellular level, rare cancer cells cease proliferation and survive chemotherapy and disseminate disease. We created a suspension culture model of high-grade serous ovarian cancer (HGSOC) dormancy and devised a novel CRISPR screening approach to identify survival genes in this context. In combination with RNA-seq, we discovered the Netrin signaling pathway as critical to dormant HGSOC cell survival. We demonstrate that Netrin-1, –3, and its receptors are essential for low level ERK activation to promote survival, and that Netrin activation of ERK is unable to induce proliferation. Deletion of all UNC5 family receptors blocks Netrin signaling in HGSOC cells and compromises viability during the dormancy step of dissemination in xenograft assays. Furthermore, we demonstrate that Netrin-1 and –3 overexpression in HGSOC correlates with poor outcome. Specifically, our experiments reveal that Netrin overexpression elevates cell survival in dormant culture conditions and contributes to greater spread of disease in a xenograft model of abdominal dissemination. This study highlights Netrin signaling as a key mediator HGSOC cancer cell dormancy and metastasis.
-
- Cancer Biology
- Cell Biology
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of ß-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which oncogenic ß-catenin affects immune surveillance remain unclear. Herein, we highlighted the involvement of ß-catenin in the regulation of the exosomal pathway and, by extension, in immune/cancer cell communication in hepatocellular carcinoma (HCC). We showed that mutated ß-catenin represses expression of SDC4 and RAB27A, two main actors in exosome biogenesis, in both liver cancer cell lines and HCC patient samples. Using nanoparticle tracking analysis and live-cell imaging, we further demonstrated that activated ß-catenin represses exosome release. Then, we demonstrated in 3D spheroid models that activation of β-catenin promotes a decrease in immune cell infiltration through a defect in exosome secretion. Taken together, our results provide the first evidence that oncogenic ß-catenin plays a key role in exosome biogenesis. Our study gives new insight into the impact of ß-catenin mutations on tumor microenvironment remodeling, which could lead to the development of new strategies to enhance immunotherapeutic response.
